Supporting the € 14.6M raise of convertible bonds of Promethera® Biosciences
Promethera® Biosciences SA, a global innovator in cell-based medicines and liver diseases, aims to deliver life-saving treatments for patients needing liver transplantation by offering a potential alternative. Promethera®’s lead program, HepaStem™, consists of intact liver-derived stem cells that can support liver tissue regeneration, and is currently being evaluated in Phase 2 clinical trials for both NASH and ACLF.
With HepaStem™ Promethera® expects to make important progress in their plan to develop the world’s first cell-based treatment for severe chronic and acute liver diseases as a tangible alternative to liver transplantation.
To strengthen the financial resources and to accelerate the HepaStem program Agio contributed to Promethera®´s issuance of convertible bonds end of 2018 by introducing the company to possible investors in the greater China region, and supported by adding the China-based CMBCC Co-High Medical Investment Fund (Hong Kong) as investor in Promethera®.
For more information read the full press release.